Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.

IF 2.6 Q2 CLINICAL NEUROLOGY

Journal of Central Nervous System Disease Pub Date : 2024-05-05 eCollection Date: 2024-01-01 DOI:10.1177/11795735241249644

Christoph Friedli, Nik Krajnc, Helly N Hammer, Stefanie Marti, Tobias Zrzavy, Maria E Evangelopoulos, Ioanna Kapsali, Paulus Rommer, Thomas Berger, Andrew Chan, Gabriel Bsteh, Robert Hoepner

{"title":"Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.","authors":"Christoph Friedli, Nik Krajnc, Helly N Hammer, Stefanie Marti, Tobias Zrzavy, Maria E Evangelopoulos, Ioanna Kapsali, Paulus Rommer, Thomas Berger, Andrew Chan, Gabriel Bsteh, Robert Hoepner","doi":"10.1177/11795735241249644","DOIUrl":null,"url":null,"abstract":"Introduction: Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 (cluster of differentiation) monoclonal antibodies (mAbs) such as ocrelizumab (OCR) and ofatumumab (OFA) show a reduction mainly of B-lymphocytes, but also other lymphocyte subsets can be affected by these treatments. There is limited data on differences between lymphocyte subset counts of pwMS after treatment initiation with OCR or OFA.Objective: To compare lymphocyte subset counts after treatment initiation in pwMS treated with OCR and OFA.Methods: We analyzed 22 pwMS initiated on OFA and 56 sex-, age- and MS course matched pwMS initiated on OCR from 2 prospectively collected observational MS databases (Bern [n: OFA 14, OCR 44] and Vienna [n: OFA 8, OCR 12]) statistically comparing lymphocyte subset counts (Mann Whitney Test).Results: We found that pwMS treated with OCR showed a stronger reduction of CD20 B-lymphocytes (P = .001), and a trend towards lower counts of CD8+ T cells (P = .056) compared to pwMS treated with OFA, whereas reduction of total lymphocyte, CD4+ lymphocyte and NK cell count was equally distributed between both treatments.Conclusion: Different effects on lymphocyte subpopulations appear to be present in pwMS after treatment initiation with different anti-CD20 mAbs. Further studies are needed to determine potential effects on anti-CD20 treatment efficacy as well as treatment associated risks such as failed vaccinations and infections.","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241249644"},"PeriodicalIF":2.6000,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11072073/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Central Nervous System Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795735241249644","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 (cluster of differentiation) monoclonal antibodies (mAbs) such as ocrelizumab (OCR) and ofatumumab (OFA) show a reduction mainly of B-lymphocytes, but also other lymphocyte subsets can be affected by these treatments. There is limited data on differences between lymphocyte subset counts of pwMS after treatment initiation with OCR or OFA.

Objective: To compare lymphocyte subset counts after treatment initiation in pwMS treated with OCR and OFA.

Methods: We analyzed 22 pwMS initiated on OFA and 56 sex-, age- and MS course matched pwMS initiated on OCR from 2 prospectively collected observational MS databases (Bern [n: OFA 14, OCR 44] and Vienna [n: OFA 8, OCR 12]) statistically comparing lymphocyte subset counts (Mann Whitney Test).

Results: We found that pwMS treated with OCR showed a stronger reduction of CD20 B-lymphocytes (P = .001), and a trend towards lower counts of CD8⁺ T cells (P = .056) compared to pwMS treated with OFA, whereas reduction of total lymphocyte, CD4⁺ lymphocyte and NK cell count was equally distributed between both treatments.

Conclusion: Different effects on lymphocyte subpopulations appear to be present in pwMS after treatment initiation with different anti-CD20 mAbs. Further studies are needed to determine potential effects on anti-CD20 treatment efficacy as well as treatment associated risks such as failed vaccinations and infections.

查看原文本刊更多论文

接受ofatumumab和ocrelizumab治疗的多发性硬化症患者的不同淋巴细胞计数：一项回顾性观察研究

简介：接受抗 CD20（分化群）单克隆抗体（mAbs）治疗的多发性硬化症患者（pwMS），如奥克立珠单抗（OCR）和ofatumumab（OFA），主要表现为 B 淋巴细胞减少，但其他淋巴细胞亚群也会受到这些治疗的影响。目前有关接受 OCR 或 OFA 治疗后 pwMS 淋巴细胞亚群计数差异的数据有限：比较接受 OCR 和 OFA 治疗的 pwMS 在开始治疗后的淋巴细胞亚群计数：我们分析了22名接受OFA治疗的pwMS和56名接受OCR治疗的与性别、年龄和MS病程相匹配的pwMS，这些pwMS来自2个前瞻性收集的MS观察数据库（伯尔尼[n: OFA 14, OCR 44]和维也纳[n: OFA 8, OCR 12]），我们通过统计学方法比较了淋巴细胞亚群计数（曼惠特尼检验）：结果：我们发现，与接受 OFA 治疗的 pwMS 相比，接受 OCR 治疗的 pwMS 的 CD20 B 淋巴细胞减少幅度更大（P = .001），CD8+ T 细胞数量呈下降趋势（P = .056），而总淋巴细胞、CD4+ 淋巴细胞和 NK 细胞数量的减少幅度在两种治疗方法中分布相当：结论：用不同的抗 CD20 mAbs 开始治疗后，似乎对 pwMS 的淋巴细胞亚群有不同的影响。需要进一步研究以确定对抗 CD20 治疗效果的潜在影响以及治疗相关风险，如疫苗接种失败和感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Central Nervous System Disease CLINICAL NEUROLOGY-

CiteScore

6.90

自引率

0.00%

发文量

审稿时长

8 weeks